Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...
Zacks Investment Research on MSN1d
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track TagSanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...
Zacks Investment Research on MSN1d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...
Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib ...
GlobalData on MSN1d
FDA fast tracks Sanofi’s mRNA vaccine for chlamydiaSanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback